Abstract
Effective drug development depends on understanding and optimizing results from controlled clinical trials. A recent double-blind, randomized, controlled trial of the treatment of agitation in patients with Alzheimers disease (AD) found no difference among the four arms of the study: haloperidol, trazodone, behavioral therapy, placebo. The current analysis was undertaken to further investigate the issues bearing on this outcome and to identify better means of detecting psychotropic effects in trials involving patients with AD. This was post hoc analysis of a clinical trial data set. Patients in the placebo group were divided into responders (25% reduction in symptoms), worseners (25% worsening in baseline agitation scores), and those without a change in symptoms. Analysis of the trial outcomes demonstrated that the reduction observed in the placebo group was of the same magnitude as predicted by regression to the mean. Patients exhibiting greater improvement had more severe baseline behavioral disturbances. The relatively modest severity of agitation and the low medication doses achieved in the study may have further contributed to the failure to distinguish among treatment groups. Research design adjustments such as collection of both screening and baseline measures to determine eligibility may limit the effects of regression to the mean on trial outcomes and reduce this challenge to clinical trials.
Keywords: randomized controlled trials, alzheimers disease, psychotropic agents, placebo, pharmacotherapy, haloperidol, behavior rating scale
Current Alzheimer Research
Title: Regression to the Mean: Implications for Clinical Trials of Psychotropic Agents in Dementia
Volume: 1 Issue: 4
Author(s): Jeffrey L. Cummings, Rochelle E. Tractenberg, Anthony Gamst, Linda Teri, Donna Masterman and Leon J. Thal
Affiliation:
Keywords: randomized controlled trials, alzheimers disease, psychotropic agents, placebo, pharmacotherapy, haloperidol, behavior rating scale
Abstract: Effective drug development depends on understanding and optimizing results from controlled clinical trials. A recent double-blind, randomized, controlled trial of the treatment of agitation in patients with Alzheimers disease (AD) found no difference among the four arms of the study: haloperidol, trazodone, behavioral therapy, placebo. The current analysis was undertaken to further investigate the issues bearing on this outcome and to identify better means of detecting psychotropic effects in trials involving patients with AD. This was post hoc analysis of a clinical trial data set. Patients in the placebo group were divided into responders (25% reduction in symptoms), worseners (25% worsening in baseline agitation scores), and those without a change in symptoms. Analysis of the trial outcomes demonstrated that the reduction observed in the placebo group was of the same magnitude as predicted by regression to the mean. Patients exhibiting greater improvement had more severe baseline behavioral disturbances. The relatively modest severity of agitation and the low medication doses achieved in the study may have further contributed to the failure to distinguish among treatment groups. Research design adjustments such as collection of both screening and baseline measures to determine eligibility may limit the effects of regression to the mean on trial outcomes and reduce this challenge to clinical trials.
Export Options
About this article
Cite this article as:
Cummings L. Jeffrey, Tractenberg E. Rochelle, Gamst Anthony, Teri Linda, Masterman Donna and Thal J. Leon, Regression to the Mean: Implications for Clinical Trials of Psychotropic Agents in Dementia, Current Alzheimer Research 2004; 1 (4) . https://dx.doi.org/10.2174/1567205043332027
DOI https://dx.doi.org/10.2174/1567205043332027 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Directions for Dementia
Current Neurovascular Research Off-Label Prescribing of Antipsychotics in Adults, Children and Elderly Individuals: A Systematic Review of Recent Prescription Trends
Current Pharmaceutical Design Platelet Activating Factor/Platelet Activating Factor Receptor Pathway as a Potential Therapeutic Target in Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Editorial [The Multifactorial Nature of Alzheimers Disease and Related Therapeutic Strategies (Executive Editors: Maria do Carmo Carreiras and Jose Marco-Contelles)]
Current Pharmaceutical Design Apoptosis and Acute Brain Ischemia in Ischemic Stroke
Current Vascular Pharmacology Meet Our Editorial Board Member
Current Hypertension Reviews The Chemistry and Bio-Medicinal Significance of Pyrimidines & Condensed Pyrimidines
Current Topics in Medicinal Chemistry Subjective Spatial Navigation Complaints - A Frequent Symptom Reported by Patients with Subjective Cognitive Decline, Mild Cognitive Impairment and Alzheimer's Disease
Current Alzheimer Research Dorsal Stream Dysfunction in Children. A Review and an Approach to Diagnosis and Management
Current Pediatric Reviews Nicotinic Receptors in Neurodegeneration
Current Neuropharmacology Intracompartmental Delivery of CNTF as Therapy for Huntingtons Disease and Retinitis Pigmentosa
Current Gene Therapy Rivastigmine for Refractory REM Behavior Disorder in Mild Cognitive Impairment
Current Alzheimer Research The Key Role of Membranes in Amyloid Formation from a Biophysical Perspective
Current Protein & Peptide Science Advances in Structural Modifications and Biological Activities of Berberine: An Active Compound in Traditional Chinese Medicine
Mini-Reviews in Medicinal Chemistry Transgenic Mouse Models of Parkinsons Disease and Huntingtons Disease
CNS & Neurological Disorders - Drug Targets Involvement of Gaucher Disease Mutations in Parkinson Disease
Current Protein & Peptide Science Heparin Induced Thrombocytopenia: Pathogenetic, Clinical, Diagnostic and Therapeutic Aspects
Cardiovascular & Hematological Disorders-Drug Targets Immunological Therapeutic and Imaging Approaches for Prion Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents HIV-1 TAT and IMMUNE DYSREGULATION in AIDS PATHOGENESIS: a THERAPEUTIC TARGET
Current Drug Targets Calcitonin Gene-Related Family Peptides in Vascular Adaptations, Uteroplacental Circulation, and Fetal Growth
Current Vascular Pharmacology